Device Trial Radar · NCT04289480
Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
164
Actual
Start
Jul 30, 2020
Primary completion
Apr 22, 2022
Study completion Jul 26, 2026
Sponsor
- Lead sponsor
- Medos International SARLNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Johnson & Johnson Medical (Shanghai) Ltd.
- First posted
- Feb 28, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to evaluate the safety and effectiveness of ENTERPRISE 2 vascular reconstruction device and delivery system (hereinafter referred to as ENTERPRISE 2) to facilitate endovascular coil embolization of intracranial aneurysms.
Conditions
- Intracranial Aneurysm
Interventions
ENTERPRISE 2 deviceDevice
The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of aneurysm recanalizationTime frame: at 180 days post procedure
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.